Protagonist Therapeutics
PTGX
144 hedge funds and large institutions have $946M invested in Protagonist Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 40 reducing their positions, and 40 closing their positions.
970% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $1.14M
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
0.52% less ownership
Funds ownership: 99.1% → 98.58% (-0.52%)
14% less funds holding
Funds holding: 167 → 144 (-23)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
40% less capital invested
Capital invested by funds: $1.57B → $946M (-$621M)
58% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$38.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$21.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.1M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$41.4M |
| 2 |
Holocene Advisors
New York
|
-$22.2M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15.3M |
| 4 |
AG
Artal Group
Luxembourg
|
-$13.8M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$11.8M |
PTGX Hedge Fund Activity: Q3 2023 in Review
144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2023, worth a combined $946M — down 40% from $1.57B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PTGX and 17 opened new positions — a net loss of 23 holders — while 40 trimmed existing stakes and 65 added.
The largest buyer was BVF Inc, adding an estimated $38.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $41.4M sold.
- 144 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2023, down from 167 in Q2 2023.
- Funds reported $946M of Protagonist Therapeutics stock for Q3 2023, down 40% quarter-over-quarter.
- 17 funds opened new Protagonist Therapeutics positions in Q3 2023 and 40 closed out, a net change of -23 holders.
- The largest Protagonist Therapeutics buyer in Q3 2023 was BVF Inc, an estimated $38.2M added.
- The largest Protagonist Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $41.4M sold.
Based on aggregated 13F filings for Q3 2023.